Skip to main content
Article thumbnail
Location of Repository

No pills for poor people? Understanding the disembowelment of India’s patent regime

By Dwijen Rangnekar

Abstract

The recent amendment to the Patent Act, 1970 brings India into full compliance with its obligations under the TRIPs Agreement, in particular allowing for product patents in the area of pharmaceuticals and agrichemicals. This amendment, the third to the 1970 Act, was characterised by a relatively muted rhetoric and a remarkable level of shared consensus amongst campaigners and critics. Focusing largely on domestic compulsions, as opposed to the global, the paper explores whether the shared consensus sets too narrow an agenda for patent reform. The paper suggests that the limits to implementing TRIPs are equally on account of ambivalence within the government with respect to intellectual property and the changing self- interest of sections of Indian pharma. Thus, despite a favourable international climate in the area of intellectual property (read Seattle, Cancun and Doha), the patent reform in India has been doubly constrained by the narrow agenda and domestic factors

Topics: JZ, HD, K1
Publisher: University of Warwick. Centre for the Study of Globalisation and Regionalisation
Year: 2005
OAI identifier: oai:wrap.warwick.ac.uk:1926

Suggested articles

Citations

  1. (2004). A bitter pill for aam admi,
  2. (2005). A confusing patent law for India, Economic and Political Weekly,
  3. (2005). A tempered patents regime,
  4. (2005). AIDS drugs threatened,
  5. (2005). Available at www.cptech.org; last accessed 26
  6. (2005). Available at www.cptech.org; last accessed 30
  7. (2005). Available at www.hinduonnet.com; last accessed 7
  8. (2005). Available at www.indianexpress.com; last accessed 21
  9. (2004). Available at www.nybooks.com; last accessed 4
  10. (2005). Changes in the new patents bill, 22 March. Available at www.cptech.org; last accessed 26
  11. (2002). Changing Patterns of Pharmaceutical Innovation, NIHCM. Available at http://www.nihcm.org/innovations.pdf; last accessed 20
  12. (2002). Commission on Intellectual Property Rights (2001): Notes on the India field-trip. Available at www.iprcommission.org; last accessed 14
  13. (2003). Decision of the General Council on implementing
  14. (1990). Delinking: Towards a Polycentric World, Zed Books, London Anon. doi
  15. (1999). Disquiet over a new regime,
  16. (2001). Dr Anji Reddy becomes new president of Indian Pharmaceutical Alliance,
  17. (1995). Encountering Development: The Making and Unmaking of the Third World, doi
  18. (2000). From free riders to fair followers: Global competition under the TRIPs Agreement,
  19. (2000). GATT, TRIPs and patent law,
  20. (1995). Global Intellectual Property Rights in information: doi
  21. (1999). Globalisation, pharmaceutical pricing and South African health policy: Managing confrontation with US firms and politicians’, doi
  22. (2004). Govt. probes over-pricing of generic drugs, The Indian Express, 28 July. Available at www.indianexpress.com; last accessed 7
  23. (1999). How many aspirins to the Rupee? Runaway drug prices,
  24. (2005). Important changes incorporated in the Patents (Amendment) Bill
  25. (2005). India and the international patent system, in
  26. (2002). India, the pharmaceutical industry and the validity of TRIPs, doi
  27. (2005). India’s choice,
  28. (2005). India’s crackdown on fakes,
  29. (2001). Indian CIPRO copies don’t pay off,
  30. (1989). Intellectual Property Rights in the Uruguay Round: A disaster for the South?” Economic and Political Weekly,
  31. (2002). Intellectual property rights, technology and economic development: experiences of Asian countries, doi
  32. (1973). International patenting and the less developed countries, doi
  33. (2004). Joint action committee against amendment of the Indian Patent Act
  34. (2003). Making global trade work for people, doi
  35. (2001). Notes of Dissent, The Patents (Second Amendment) Bill,
  36. (1995). One step forward, many steps back: doi
  37. (2005). Padmashree (2005): Economic aspects of access to medicine after 2005: Product patent protection and emerging firm strategies in the Indian pharmaceutical industry. Paper commissioned by the CIPIH, World Health Organisation Gopalkumar,
  38. (1998). Patent capitulation,
  39. (2005). Patent debate: An unhealthy plan for the poor, The Indian Express,
  40. (2002). Plant breeding in an era of privatisation: reflections on transformations in the Indian seed industry,
  41. (1998). Power and Ideas: North-South Politics of Intellectual Property and Antitrust. doi
  42. (1998). Protecting proprietary and security rights in cyberspace: Initiatives in India, paper presented at Info-ethics ’98, UNESCO. Available at http://www.unesco.org/webworld/infoethics_2/eng/papers/paper_15.htm; last accessed 27
  43. (2000). R&D capability and alliance formation in the pharmaceutical industry doi
  44. (2005). Rao (2005a): Third amendment of the Indian Patents Act, 10 January. Available at www.ased.org; last accessed 31
  45. Rao (2005b): Reflections on a TRIPs-Compliant law,
  46. (2001). Re-thinking trips in the WTO: NGOs demand review and reform
  47. (1990). Recolonization: GATT, the Uruguay Round and the Third World, Third World Network, Penang. doi
  48. (1959). Report on the Revision of the Patent Law,
  49. (2005). Resource Book on TRIPs and Development, Chapter 31, Available at www.iprsonline.org; last accessed 20 doi
  50. (2002). Special 301’ Submission of PhRMA for the "Special 301" Report on Intellectual Property Barriers, 12 September. Available at http://www.phrma.org/international/special301/india.cfm; last accessed 27
  51. (2004). Statement on the Ordinance relating to Patents (Third) Amendment,
  52. (2004). Suggestions for Patents (Third) Amendment Bill to Amendment the Indian Patents Act 1970, available at www.phmovement.org/india; last accessed 31
  53. (1999). Technology, marketing and risk in the evolution of the pharmaceutical industry, in
  54. (2005). The draft patent law,
  55. (2005). The Glivec case, Frontline,
  56. (2004). The Indian pharmaceutical industry and consumer welfare: Prospects under the TRIPs Regime,
  57. (1998). The introduction of pharmaceutical product patents in India: ‘Heartless exploitation of the poor and suffering’? doi
  58. (1994). The Nelson-Winter-Dosi model and synthetic dye chemistry’
  59. (1972). The new Indian patents law,
  60. (1999). The patents roller-coaster, The Indian Express,
  61. (1986). The political economy of the pharmaceutical industry,
  62. (1964). The Role of Patents in the Transfer of Technology to Developing Countries, United Nations, doi
  63. (2002). The TRIPs agreement, access to medicines, and the WTO Doha ministerial conference”, doi
  64. (2004). The truth about the drug companies,
  65. (1998). This patent bill won’t please WTO, The Economic Times,
  66. (2001). US, Brazil withdraw HIV/AIDS dispute from WTO litigation, 25 June. Available at http://usinfo.state.gov/topical/econ/group8/summit01/wwwh01062512.html; last accessed 30
  67. (2004). Using ideas strategically: The contest between business and NGO networks in intellectual property rights, doi
  68. WTO (2000b): Brazil – Measures affecting patent protection: Request for consultation by the United States, WT/DS199/1, dated 8
  69. WTO (2001a): Brazil – Measures affecting patent protection: Request for the establishment of a panel by the United States, WT/DS199/3, dated 9
  70. WTO (2001b): Declaration on the TRIPs Agreement and public health, doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.